Cargando…

Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression

SIMPLE SUMMARY: Benzene is produced by diverse petroleum transformation processes and it is widely employed in industry despite its oncogenic effects. In fact, occupational exposure to benzene may cause hematopoietic malignancy. The leukemogenic action of benzene is particularly complex. Possible pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Spatari, Giovanna, Allegra, Alessandro, Carrieri, Mariella, Pioggia, Giovanni, Gangemi, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156840/
https://www.ncbi.nlm.nih.gov/pubmed/34069279
http://dx.doi.org/10.3390/cancers13102392
_version_ 1783699543375740928
author Spatari, Giovanna
Allegra, Alessandro
Carrieri, Mariella
Pioggia, Giovanni
Gangemi, Sebastiano
author_facet Spatari, Giovanna
Allegra, Alessandro
Carrieri, Mariella
Pioggia, Giovanni
Gangemi, Sebastiano
author_sort Spatari, Giovanna
collection PubMed
description SIMPLE SUMMARY: Benzene is produced by diverse petroleum transformation processes and it is widely employed in industry despite its oncogenic effects. In fact, occupational exposure to benzene may cause hematopoietic malignancy. The leukemogenic action of benzene is particularly complex. Possible processes of onset of hematological malignancies have been recognized as a genotoxic action and the provocation of immunosuppression. However, benzene can induce modifications that do not involve alterations in the DNA sequence, the so-called epigenetics changes. Acquired epigenetic modification may also induce leukemogenesis, as benzene may alter nuclear receptors, and cause changes at the protein level, thereby modifying the function of regulatory proteins, including oncoproteins and tumor suppressor proteins. ABSTRACT: Benzene carcinogenic ability has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms. Benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas. Possible mechanisms of benzene initiation of hematological tumors have been identified, as a genotoxic effect, an action on oxidative stress and inflammation and the provocation of immunosuppression. However, it is becoming evident that genetic alterations and the other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies. Acquired epigenetic alterations may participate with benzene leukemogenesis, as benzene may affect nuclear receptors, and provoke post-translational alterations at the protein level, thereby touching the function of regulatory proteins, comprising oncoproteins and tumor suppressor proteins. DNA hypomethylation correlates with stimulation of oncogenes, while the hypermethylation of CpG islands in promoter regions of specific tumor suppressor genes inhibits their transcription and stimulates the onset of tumors. The discovery of the systems of epigenetic induction of benzene-caused hematological tumors has allowed the possibility to operate with pharmacological interventions able of stopping or overturning the negative effects of benzene.
format Online
Article
Text
id pubmed-8156840
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81568402021-05-28 Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression Spatari, Giovanna Allegra, Alessandro Carrieri, Mariella Pioggia, Giovanni Gangemi, Sebastiano Cancers (Basel) Review SIMPLE SUMMARY: Benzene is produced by diverse petroleum transformation processes and it is widely employed in industry despite its oncogenic effects. In fact, occupational exposure to benzene may cause hematopoietic malignancy. The leukemogenic action of benzene is particularly complex. Possible processes of onset of hematological malignancies have been recognized as a genotoxic action and the provocation of immunosuppression. However, benzene can induce modifications that do not involve alterations in the DNA sequence, the so-called epigenetics changes. Acquired epigenetic modification may also induce leukemogenesis, as benzene may alter nuclear receptors, and cause changes at the protein level, thereby modifying the function of regulatory proteins, including oncoproteins and tumor suppressor proteins. ABSTRACT: Benzene carcinogenic ability has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms. Benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas. Possible mechanisms of benzene initiation of hematological tumors have been identified, as a genotoxic effect, an action on oxidative stress and inflammation and the provocation of immunosuppression. However, it is becoming evident that genetic alterations and the other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies. Acquired epigenetic alterations may participate with benzene leukemogenesis, as benzene may affect nuclear receptors, and provoke post-translational alterations at the protein level, thereby touching the function of regulatory proteins, comprising oncoproteins and tumor suppressor proteins. DNA hypomethylation correlates with stimulation of oncogenes, while the hypermethylation of CpG islands in promoter regions of specific tumor suppressor genes inhibits their transcription and stimulates the onset of tumors. The discovery of the systems of epigenetic induction of benzene-caused hematological tumors has allowed the possibility to operate with pharmacological interventions able of stopping or overturning the negative effects of benzene. MDPI 2021-05-14 /pmc/articles/PMC8156840/ /pubmed/34069279 http://dx.doi.org/10.3390/cancers13102392 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Spatari, Giovanna
Allegra, Alessandro
Carrieri, Mariella
Pioggia, Giovanni
Gangemi, Sebastiano
Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
title Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
title_full Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
title_fullStr Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
title_full_unstemmed Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
title_short Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
title_sort epigenetic effects of benzene in hematologic neoplasms: the altered gene expression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156840/
https://www.ncbi.nlm.nih.gov/pubmed/34069279
http://dx.doi.org/10.3390/cancers13102392
work_keys_str_mv AT spatarigiovanna epigeneticeffectsofbenzeneinhematologicneoplasmsthealteredgeneexpression
AT allegraalessandro epigeneticeffectsofbenzeneinhematologicneoplasmsthealteredgeneexpression
AT carrierimariella epigeneticeffectsofbenzeneinhematologicneoplasmsthealteredgeneexpression
AT pioggiagiovanni epigeneticeffectsofbenzeneinhematologicneoplasmsthealteredgeneexpression
AT gangemisebastiano epigeneticeffectsofbenzeneinhematologicneoplasmsthealteredgeneexpression